日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial

单次注射洛瑞西维因治疗膝骨关节炎患者的安全性和有效性评价：一项多中心观察性扩展试验

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-024-00731-9
Swearingen, Christopher J; Tambiah, Jeyanesh R S; Simsek, Ismail; Ghandehari, Heli; Kennedy, Sarah; Yazici, Yusuf
关节炎
发表日期：2025
文献求助 收藏

Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies?

针对进行性加重且疼痛难忍的膝骨关节炎，有哪些起效缓慢的药物？我们如何评估这些潜在新疗法的获益风险比？

期刊:Osteoarthritis and Cartilage Open
影响因子:2.8
doi:10.1016/j.ocarto.2024.100546
Lane, Nancy E; Simon, Lee S; Tambiah, Jeyanesh
关节炎
发表日期：2025
文献求助 收藏

The inflammatory endotype in osteoarthritis: Reflections from the 2024 OARSI clinical trials symposium (CTS) with a special emphasis on feasibility for clinical development

骨关节炎的炎症表型：2024 年 OARSI 临床试验研讨会 (CTS) 的反思，特别关注临床开发的可行性

期刊:Osteoarthritis and Cartilage Open
影响因子:2.8
doi:10.1016/j.ocarto.2025.100572
Karsdal, Morten Asser; Rovati, Lucio C; Tambiah, Jeyanesh; Kubassova, Olga; Ladel, Christoph; Berenbaum, Francis; Bay-Jensen, Anne-Christine; Mclean, Lachy; Loeser, Richard; Mobasheri, Ali; Kraus, Virginia B
炎症/感染
关节炎
炎症
发表日期：2025
文献求助 收藏

Reflections from the OARSI 2022 clinical trials symposium: The pain of OA-Deconstruction of pain and patient-reported outcome measures for the benefit of patients and clinical trial design

来自 OARSI 2022 临床试验研讨会的反思：骨关节炎的疼痛——为了患者和临床试验设计的利益，对疼痛和患者报告结局指标进行解构

期刊:Osteoarthritis and Cartilage
影响因子:9
doi:10.1016/j.joca.2023.06.006
Karsdal, M A; Tambiah, J; Felson, D; Ladel, C; Nikolov, N P; Hodgins, D; Bihlet, A R; Neogi, T; Baatenburg de Jong, C; Bay-Jensen, A C; Baron, R; Laslop, A; Mobasheri, A; Kraus, V B
关节炎
发表日期：2023
文献求助 收藏

Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study

7天内同侧膝关节内注射皮质类固醇和洛瑞西维因的安全性、耐受性和药代动力学：一项开放标签、随机、平行组研究

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-023-00604-7
Fineman, Mark S; McAlindon, Timothy E; Lattermann, Christian; Swearingen, Christopher J; Kennedy, Sarah; Lopez, Victor A; Simsek, Ismail; Tambiah, Jeyanesh R S; Yazici, Yusuf
发表日期：2023
文献求助 收藏

Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status?

2021 年 OARSI 临床试验研讨会的反思：理解骨关节炎药物开发中生物标志物评估的注意事项 - 未来的研究应该关注疾病活动性，而不是疾病状态吗？

期刊:Osteoarthritis and Cartilage Open
影响因子:2.8
doi:10.1016/j.ocarto.2022.100262
Karsdal, M A; Tambiah, J; Hochberg, M C; Ladel, C; Bay-Jensen, A C; Arendt-Nielsen, L; Mobasheri, A; Kraus, V B
关节炎
发表日期：2022
文献求助 收藏

Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial

膝骨关节炎患者对关节内注射洛瑞西维汀的个体症状反应：一项 2B 期试验的事后分析

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-021-00316-w
Tambiah, Jeyanesh R S; Kennedy, Sarah; Swearingen, Christopher J; Simsek, Ismail; Yazici, Yusuf; Farr, Jack; Conaghan, Philip G
关节炎
发表日期：2021
文献求助 收藏

SM04755, a small-molecule inhibitor of the Wnt pathway, as a potential topical treatment for tendinopathy

SM04755 是一种 Wnt 通路的小分子抑制剂，有望成为肌腱病的一种局部治疗方法。

期刊:Journal of Orthopaedic Research
影响因子:2.3
doi:10.1002/jor.24898
Deshmukh, Vishal; Seo, Tim; O'Green, Alyssa L; Ibanez, Maureen; Hofilena, Brian; Kc, Sunil; Stewart, Joshua; Dellamary, Luis; Chiu, Kevin; Ghias, Abdullah; Barroga, Charlene; Kennedy, Sarah; Tambiah, Jeyanesh; Hood, John; Yazici, Yusuf
Wnt/β-Catenin
信号转导
发表日期：2021
文献求助 收藏

Real-World Health Care Resource Utilization and Costs Among US Patients with Knee Osteoarthritis Compared with Controls

美国膝骨关节炎患者与对照组的真实世界医疗资源利用情况和成本比较

期刊:
影响因子:
doi:10.2147/CEOR.S302289
Bedenbaugh, Angela V; Bonafede, Machaon; Marchlewicz, Elizabeth H; Lee, Vinson; Tambiah, Jeyanesh
关节炎
发表日期：2021
文献求助 收藏

Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial

Lorecivivint，一种新型关节内注射的 CDC 样激酶 2 和双特异性酪氨酸磷酸化调节激酶 1A 抑制剂及 Wnt 通路调节剂，用于治疗膝骨关节炎：一项 II 期随机试验

期刊:Arthritis & Rheumatology
影响因子:10.9
doi:10.1002/art.41315
Yazici, Yusuf; McAlindon, Timothy E; Gibofsky, Allan; Lane, Nancy E; Clauw, Daniel; Jones, Morgan; Bergfeld, John; Swearingen, Christopher J; DiFrancesco, Anita; Simsek, Ismail; Tambiah, Jeyanesh; Hochberg, Marc C
信号转导
关节炎
磷酸化
Wnt/β-Catenin
发表日期：2020
文献求助 收藏